natgillin/translations-raw huggingface dataset:
Indtag Ibandronsyre Teva mindst 6 timer efter, at du sidst har spist, drukket eller taget nogen form for anden medicin, vitaminer og mineraler eller kosttilskud (f.eks. produkter, der indeholder kalk (mælk), aluminium, magnesium og jern) andet end vand. 
Take Ibandronic Acid Teva with at least 6 hours after you had last had anything to eat, drink or any other medicines or supplements (e.g. products containing calcium (milk), aluminium, magnesium and iron) except water.
Det er fordi NSAIDer og Ibandronsyre Teva begge kan irritere din mave-tarmkanal 
This is because NSAIDs and Ibandronic Acid Teva can both irritate your stomach and gut
Ibandronsyre hæmmer selektivt osteoklastaktiviteten, reducerer knogleresorptionen og mindsker herved skeletkomplikationerne ved den maligne sygdom. 
Ibandronic acid selectively inhibits osteoclast activity, reducing bone resorption and thereby reducing skeletal complications of the malignant disease.
Måned 1 __/__/__ 
Month 1 __/__/__
Undersøgelser for genotoksicitet viste ingen tegn på genetisk aktivitet af ibandronsyre. 
Tests for genotoxicity revealed no evidence of genetic activity for ibandronic acid.
De omfatter et nedsat antal implantationssteder, forstyrrelser af den normale fødsel (dystocia), en øgning af viscerale forandringer (nyre-pelvis-ureter-syndrom) og tandabnormaliteter på F1-afkommet hos rotter. 
They include a decreased number of implantation sites, interference with natural delivery (dystocia), an increase in visceral variations (renal pelvis ureter syndrome) and teeth abnormalities in F1 offspring in rats.
Daglig behandling med 2,5 mg resulterede i en tiltagende øgning af BMD både vertebralt og nonvertebralt. 
Daily treatment with 2.5 mg resulted in progressive increases in BMD at vertebral and nonvertebral sites of the skeleton.
Din læge kan vælge at tage regelmæssige blodprøver, mens du er i behandling med Ibandronsyre Teva. 
Your doctor may do regular blood tests while you are taking Ibandronic Acid Teva.
De omfatter en nedsættelse af antallet af implantationssteder, forstyrrelser af den normale fødsel (dystocia) og en øgning af viscerale forandringer (nyre-pelvis-ureter-syndrom). 
They include a decreased number of implantation sites, interference with natural delivery (dystocia), and an increase in visceral variations (renal pelvis ureter syndrome).
• Tag din Ibandronsyre Teva-tablet udelukkende med et helt glas vand (ca. 200 ml). 
• Take your tablet with a full glass of water only (about 200 mL).
Du kan køre bil og betjene maskiner, da det forventes, at Ibandronsyre Teva ikke eller i ubetydelig grad påvirker din evne til at køre bil og betjene maskiner. 
You can drive and use machines as it's expected that Ibandronic Acid Teva has no or negligible effect on your ability to drive and use machines.
Der foreligger ikke tilstrækkelige data om brugen af ibandronsyre hos gravide kvinder. 
There are no adequate data from the use of ibandronic acid in pregnant women.
• kløe, hævelse af ansigt, læber, tunge og hals, med vejrtrækningsproblemer. 
• itching, swelling of your face, lips, tongue and throat, with difficulty breathing.
På grundlag af resultaterne fra studie BM 16549 forventes ibandronsyre 150 mg én gang om måneden at være mindst ligeså effektivt med hensyn til at forebygge frakturer som ibandronsyre 2,5 mg daglig. 
Based on the results of study BM 16549, ibandronic acid 150 mg once monthly is expected to be at least as effective in preventing fractures as ibandronic acid 2.5 mg daily.
Hos raske, mandlige forsøgspersoner og hos postmenopausale kvinder, bevirkede intravenøs ranitidin en ca. 20 % øgning i biotilgængeligheden af ibandronsyre (som ligger inden for den normale variabilitet for biotilgængeligheden af ibandronsyre), formentlig som et resultat af den reducerede gastriske surhedsgrad. 
In healthy male volunteers and postmenopausal women, intravenous ranitidine caused an increase in ibandronic acid bioavailability of about 20% (which is within the normal variability of the bioavailability of ibandronic acid), probably as a result of reduced gastric acidity.
Dette inkluderer: 
The other ingredients are:
Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG Storbritannien 
Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG United Kingdom
Dosisjustering er ikke nødvendig hos patienter med let nedsat nyrefunktion (CLcr ≥ 50 og < 80 ml/min). 
No dose adjustment is necessary for patients with mild renal impairment (CLcr ≥50 and <80 mL/min).
Den renale clearance for ibandronsyre hos patienter med forskellige grader af nedsat nyrefunktion er lineært relateret til kreatininclearance. 
Renal clearance of ibandronic acid in patients with various degrees of renal impairment is linearly related to creatinine clearance.
Tabel 1: Bivirkninger hos postmenopausale kvinder, som fik ibandronsyre 150 mg én gang månedlig eller ibandronsyre 2,5 mg daglig i fase III-studierne BM 16549 og MF 4411 samt bivirkninger set efter markedsføring. 
Table 1: Adverse reactions occurring in postmenopausal women receiving ibandronic acid 150 mg once monthly or ibandronic acid 2.5 mg daily in the phase III studies BM 16549 and MF 4411 and in post-marketing experience.
Biotilgængeligheden blev reduceret med ca. 75 % når ibandronsyre-tabletter blev indtaget 2 timer efter et standardmåltid. 
Bioavailability was reduced by approximately 75% when ibandronic acid tablets were administered 2 hours after a standard meal.
Tal med din læge eller apotekspersonalet før du tager dette lægemiddel. 
Ask your doctor or pharmacist for advice before taking this medicine.
Angioødem, ansigtsødem, urticaria 
Angioedema, Face oedema, Urticaria
• hvis du er allergisk over for ibandronsyre eller et af de øvrige indholdsstoffer i dette lægemiddel 
• if you are allergic to ibandronic acid or any of the other ingredients of this medicine that are listed in section 6
Det indeholder det aktive stof ibandronsyre. 
It contains the active substance ibandronic acid.
Anvendelse af Ibandronsyre Teva er ikke relevant hos børn under 18 år, og Ibandronsyre Teva er ikke undersøgt hos denne population (se pkt. 
There is no relevant use of Ibandronic Acid Teva in children below 18 years, and Ibandronic Acid Teva was not studied in this population (see section 5.1 and section 5.2).
• Tag ikke tabletten med andet end almindeligt vand. 
Do not take your tablet with any drink other than water.
Der er ingen farmakokinetiske data for ibandronsyre hos patienter med nedsat leverfunktion. 
There are no pharmacokinetic data for ibandronic acid in patients who have hepatic impairment.
Hvis patienterne opdager, at de har glemt at tage en Ibandronsyre Teva-tablet 150 mg, skal de tage den næste morgen forudsat, at der er mindst 7 dage til næste dosis. 
In case a dose is missed, patients should be instructed to take one Ibandronic Acid Teva 150 mg tablet the morning after the tablet is remembered, unless the time to the next scheduled dose is within 7 days.
Andelen af patienter med bivirkninger var 22,7 % og 25,0 % for ibandronsyre 150 mg én gang om måneden efter henholdsvis et og to år. 
The overall proportion of patients who experienced an adverse reaction, was 22.7 % and 25.0 % for ibandronic acid 150 mg once monthly after one and two years, respectively.
Ibandronsyre hører til bisphosphonatgruppen af forbindelser, som virker specifikt på knoglerne. 
Ibandronic acid belongs to the bisphosphonate group of compounds which act specifically on bone.
Det anbefales derfor, at tabletterne indtages efter natlig faste (mindst 6 timer), og at fasten fortsættes mindst 30 minutter efter tabletindtagelsen (se pkt. 
Therefore, it is recommended that the tablets should be taken after an overnight fast (at least 6 hours) and fasting should continue for at least 30 minutes after the dose has been taken (see section 4.2).
Kliniske studier har ikke vist tegn på forringelse af nyrefunktionen ved længerevarende ibandronsyrebehandling. 
Clinical studies have not shown any evidence of deterioration in renal function with long term ibandronic acid therapy.
Ibandronsyre Teva er kun til brug hos kvinder, der er kommet i overgangsalderen, og må ikke tages af kvinder, der stadig kan få børn. 
Ibandronic Acid Teva is for use only by postmenopausal women and must not be taken by women who could still have a baby.
Atypiske subtrochantære og diafyseale femurfrakturer † 
Atypical subtrochanteric and diaphyseal femoral fractures†
Efter indtagelse af din månedlige Ibandronsyre Teva-tablet, skal du vente 1 time, inden du tager anden medicin, herunder tabletter eller anden form for medicin mod dårlig fordøjelse, kalktilskud eller vitaminer. 
After swallowing your monthly Ibandronic Acid Teva tablet, wait for 1 hour before taking any other medication, including indigestion tablets, calcium supplements, or vitamins.
• hvis du har visse problemer med spiserøret/mavesækken, såsom indsnævring eller synkebesvær 
- If you have certain problems with your gullet/food pipe (oesophagus) such as narrowing or difficulty swallowing.
Den anbefalede dosis er én 150 mg filmovertrukket tablet én gang om måneden. 
The recommended dose is one 150 mg film-coated tablet once a month.
Influenzalignende sygdom* 
Influenza like illness*
• smerte eller ømhed i munden eller kæben. 
• pain or sore in your mouth or jaw.
• Tag din tablet så snart du står op om morgenen, før du spiser noget, drikker noget eller tager nogen form for medicin, vitaminer og mineraler eller kosttilskud. 
• Take your tablet as soon as you get up for the day before having your first food, drink, any medicine or supplements.
• tabletkerne: mikrokrystallinsk cellulose, povidon K-30, crospovidon (type A), kolloid vandfri silica, stearinsyre. 
• tablet core: cellulose microcrystalline, povidone K-30, crospovidone (type A), silica colloidal anhydrous, stearic acid;
Ibandronsyre Teva-tabletter skal indtages efter faste om natten (mindst 6 timer) og før indtagelse af dagens første mad- og drikkevarer. 
Ibandronic Acid Teva tablets should be taken after an overnight fast (at least 6 hours) and before the first food or drink of the day.
Der bør indtages mælk eller antacida med henblik på at binde Ibandronsyre Teva, og bivirkninger behandles symptomatisk. 
Milk or antacids should be given to bind Ibandronic Acid Teva, and any adverse reactions treated symptomatically.
Hos raske mandlige forsøgspersoner og hos postmenopausale kvinder medførte intravenøs administration af ranitidin en ca. 20 % øgning i biotilgængeligheden af ibandronsyre, formentlig som et resultat af den reducerede gastriske surhedsgrad. 
In healthy male volunteers and postmenopausal women, intravenous administration of ranitidine caused an increase in ibandronic acid bioavailability of about 20%, probably as a result of reduced gastric acidity.
Når lægemidlet er godkendt, er indberetning af mistænkte bivirkninger vigtig. 
Reporting suspected adverse reactions after authorisation of the medicinal product is important.
Analgetikaforbrug * 
Analgesic use *
Proteinbindingen i humant plasma er ca. 85 %-87 % (bestemt in vitro ved terapeutiske koncentrationer). 
Protein binding in human plasma is approximately 85 %-87 % (determined in vitro at therapeutic concentrations), and thus there is a low potential for interaction with other medicinal products due to displacement.
Måned 3 __/__/__ 
Month 3 __/__/__
• Kosttilskud, som indeholder kalk, magnesium, jern eller aluminium, idet de muligvis kan påvirke virkningen af Ibandronsyre Teva 
- Supplements containing calcium, magnesium, iron or aluminium, as they could possibly influence the effects of Ibandronic Acid Teva.
Børn og unge Giv ikke Ibandronsyre Teva til børn og teenagere under 18 år. 
Children and adolescents Do not give Ibandronic Acid Teva to children or adolescents below 18 years.
For patienter med svært nedsat nyrefunktion (kreatininclearance < 30 ml/min) er den anbefalede dosis én 50 mg filmovertrukket tablet én gang ugentligt. 
For patients with severe renal impairment (CLcr <30 mL/min) the recommended dose is one 50 mg film-coated tablet once weekly.
• hvis du har problemer med at synke eller har fordøjelsesproblemer 
- If you have any swallowing or digestive problems.
• tabletovertræk: titandioxid (E171), hypromellose, macrogol 400, polysorbat 80. 
• tablet coating: titanium dioxide (E 171), hypromellose, macrogol 400, polysorbate 80.
- knoglekirurgi for behandling af frakturer - vertebrale frakturer - non-vertebrale frakturer. 
- radiotherapy to bone for treatment of fractures/impending fractures, - surgery to bone for treatment of fractures, - vertebral fractures, - non-vertebral fractures.
Farmakokinetikken for ibandronsyre blev ikke undersøgt hos patienter med terminal nyresygdom behandlet med andet end hæmodialyse. 
The pharmacokinetics of ibandronic acid was not assessed in patients with end-stage renal disease managed by other than hemodialysis.
MARKEDSFØRINGSTILLADELSESNUMMER (NUMRE) EU/1/10/642/001 28 filmovertrukne tabletter 
MARKETING AUTHORISATION NUMBER(S) EU/1/10/642/001 28 film-coated tablets
Patienterne skal derfor faste natten over (mindst 6 timer) inden indtagelse af Ibandronsyre Teva og fortsætte med at faste 1 time efter indtagelsen af Ibandronsyre Teva (se pkt. 
Therefore, patients should fast overnight (at least 6 hours) before taking Ibandronic Acid Teva and continue fasting for 1 hour following intake of Ibandronic Acid Teva (see section 4.2).
Hvis du får disse symptomer, skal du straks stoppe med at tage Ibandronsyre Teva og kontakte lægen (se punkt 3). 
If you develop these symptoms, stop taking Ibandronic Acid Teva and tell your doctor straight away (see section 3).
Der er anført en 2D-stregkode, som indeholder en entydig identifikator. 
UNIQUE IDENTIFIER - 2D BARCODE 2D barcode carrying the unique identifier included.
Lad være med at tygge, sutte, eller knuse tabletten. 
Do not chew, suck or crush the tablet.
Brug ikke lægemidlet efter den udløbsdato, der står på blisteren og pakningen efter EXP. Udløbsdatoen er den sidste dag i den nævnte måned. 
Do not use this medicine after the expiry date which is stated on the blister and carton after EXP.
Anafylaktisk reaktion/shock*† 
Anaphylactic reaction/shock*
Den sædvanlige dosis Ibandronsyre Teva er 1 tablet én gang om måneden. 
The usual dose of Ibandronic Acid Teva is one tablet once a month.
Måned 2 __/__/__ 
Month 2 __/__/__
Det er fordi, der kan forekomme irritation, betændelse eller sårdannelse i spiserøret/mavesækken. 
This is because it can cause irritation, inflammation or ulcers in your food pipe/gullet (oesophagus).
Ibandronsyre Teva 150 mg: Lægemidlet er receptpligtigt. 
Ibandronic Acid Teva 150 mg: Medicinal product subject to medical prescription.
Ibandronsyre Teva er kun til brug hos postmenopausale kvinder og må ikke anvendes af fertile kvinder. 
Ibandronic Acid Teva is only for use in postmenopausal women and must not be taken by women of childbearing potential.
• Indtag Ibandronsyre Teva-tabletten mindst 6 timer efter, at du sidst har spist eller drukket, bortset fra vand. 
- Take your Ibandronic Acid Teva tablet at least 6 hours after you last had anything to eat or drink except water.
Derefter skal de igen tage en tablet én gang om måneden som oprindeligt planlagt. 
Patients should then return to taking their dose once a month on their originally scheduled date.
Studier med rotter har vist en vis reproduktionstoksisitet (se pkt. 
Studies in rats have shown some reproductive toxicity (see section 5.3).
- Patienterne må ikke lægge sig ned før 60 minutter efter indtagelse af Ibandronsyre Teva. 
- Patients should not lie down for 60 minutes after taking Ibandronic Acid Teva.
I et toårs studie hos postmenopausale kvinder med osteoporose (BM 16549) var sikkerheden af ibandronsyre 150 mg én gang om måneden den samme som for ibandronsyre 2,5 mg daglig. 
In a two-year study in postmenopausal women with osteoporosis (BM 16549) the overall safety of ibandronic acid 150 mg once monthly and ibandronic acid 2.5 mg daily was similar.
Ibandronsyre medfører hos postmenopausale kvinder en tiltagende forøgelse af knoglemassen og en nedsat frakturhyppighed ved en reduktion af den øgede knogleomsætning hen imod et præmenopausalt niveau. 
Ibandronic acid leads to progressive net gains in bone mass and a decreased incidence of fractures through the reduction of elevated bone turnover towards premenopausal levels in postmenopausal women.
Du kan have en alvorlig betændelse i spiserøret, muligvis med sår, eller forsnævringer i spiserøret 
You may have a severe inflammation of your gullet/food pipe, possibly with sores or constriction of the gullet/food pipe
Ibandronsyre Teva tilhører en medicingruppe, som kaldes bisphosphonater. 
Ibandronic Acid Teva belongs to a group of medicines called bisphosphonates.
• Tag én Ibandronsyre Teva 150 mg tablet én gang om måneden. 
- Take one Ibandronic Acid Teva 150 mg tablet once a month.
Dosering Den anbefalede dosis er én 50 mg filmovertrukket tablet dagligt. 
Posology The recommended dose is one 50 mg film-coated tablet daily.
Azotæmi (uræmi) 
Azotaemia (uraemia)
Det er vigtigt at alle patienter indtager tilstrækkeligt calcium og vitamin D. 
Adequate intake of calcium and vitamin D is important in all patients.
Informer din læge, hvis du er i gang med en tandbehandling eller vil få foretaget en tandoperation (f.eks. tandudtrækning), og fortæl ligeledes din tandlæge, at du er i behandling med Ibandronsyre Teva. 
If you are under dental treatment or will undergo dental surgery (e.g. tooth extractions), inform your doctor about your dental treatment and tell your dentist that you are being treated with Ibandronic Acid Teva.
Eksisterende hypokalcæmi skal behandles, før behandling med Ibandronsyre Teva initieres. 
Existing hypocalcaemia must be corrected before starting Ibandronic Acid Teva therapy.
Knogleresorptionen ved malign sygdom karakteriseres ved en udtalt knogleresorption som ikke modsvares af en tilsvarende knogleformation. 
Bone resorption due to malignant disease is characterized by excessive bone resorption that is not balanced with appropriate bone formation.
Eksponering af ibandronsyre hos patienter med forskellige grader af nedsat nyrefunktion er relateret til kreatininclearance (CLcr ). 
Patients with renal impairment Exposure to ibandronic acid in patients with various degree of renal impairment is related to creatinine clearance (CLcr).
Ibandronsyre 50 mg n=287 
Ibandronic acid 50 mg n=287
Hos patienter med moderat nedsat nyrefunktion (CLcr ≥ 30 og < 50 ml/min) eller svært nedsat nyrefunktion (CLcr < 30 ml/min) anbefales dosisjustering (se pkt. 
For patients with moderate renal impairment (CLcr ≥30 and <50 mL/min) or severe renal impairment (CLcr <30 mL/min) an adjustment in the dose is recommended (see section 4.2).
Den farmakodynamiske virkning af ibandronsyre er hæmning af knogleresorptionen. 
The pharmacodynamic action of ibandronic acid is inhibition of bone resorption.
Børn og teenagere Ibandronsyre Teva må ikke anvendes til børn og teenagere under 18 år. 
Children and adolescents Ibandronic Acid Teva should not be used in children and adolescents below the age of 18 years.
Hvis der er usikkerhed omkring et eventuelt for højt kalkindhold i postevandet, anbefales det at bruge vand på flaske med et lavt mineralindhold. 
If there is a concern regarding potentially high levels of calcium in the tap water (hard water), it is advised to use bottled water with a low mineral content.
Forhøjet parathyroideahor mon i blodet 
Blood parathyroid hormone increased
Tag ikke Ibandronsyre Teva, hvis du er gravid eller ammer. 
Do not take Ibandronic Acid Teva if you are pregnant or breast feeding.
EU/1/10/642/003 1 filmovertrukne tabletter i PVC/Aclar/PVC - Aluminiumsblistre kartonæsker EU/1/10/642/004 3 filmovertrukne tabletter i PVC/Aclar/PVC - Aluminiumsblistre i kartonæsker 
EU/1/10/642/003 1 film-coated tablet in PVC/Aclar/PVC - Aluminium blister in cardboard boxes EU/1/10/642/004 3 film-coated tablets in PVC/Aclar/PVC - Aluminium blisters in cardboard boxes
Bivirkningerne ved ibandronsyre hos rotter i reproduktions-toksicitets-undersøgelserne var de samme som for denne gruppe lægemidler (bisphosphonater). 
Adverse effects of ibandronic acid in reproductive toxicity studies in the rat were those expected for this class of medicinal products (bisphosphonates).
Dette skyldes, at Ibandronsyre Teva kan påvirke den måde anden medicin virker på, ligesom anden medicin kan påvirke den måde, hvorpå Ibandronsyre Teva virker. 
This is because Ibandronic Acid Teva can affect the way some other medicines work.
• Hvis du glemmer at tage din tablet om morgenen på den valgte dag, må du ikke tage tabletten senere på dagen. 
If you forget to take Ibandronic Acid Teva - If you forget to take your tablet on the morning of your chosen day, do not take a tablet later in the day.
Tilfælde af knoglenekrose i kæben er blevet rapporteret, overvejende hos kræftpatienter i behandling med lægemidler, der hæmmer knogleresorption, såsom ibandronsyre (se pkt. 
Cases of osteonecrosis of the jaw have been reported, predominantly in cancer patients treated with medicinal products that inhibit bone resorption, such as ibandronic acid (see section 4.4.)
Der er ikke tegn på, at ibandronsyre metaboliseres i dyr eller mennesker. 
Biotransformation There is no evidence that ibandronic acid is metabolised in animals or humans.
De alvorligste rapporterede bivirkninger er anafylaktisk reaktion/shock, atypiske femurfrakturer, knoglenekrose i kæben, gastrointestinal irritation og inflammation i øjet (se afsnit ”Beskrivelse af udvalgte bivirkninger” og pkt. 
The most serious reported adverse reactions are anaphylactic reaction/shock, atypical fractures of the femur, osteonecrosis of the jaw, gastrointestinal irritation, and ocular inflammation (see paragraph “Description of selected adverse reactions” and section 4.4).
EU/1/10/642/001 28 filmovertrukne tabletter i PVC/Aclar/PVC - Aluminiumblistre i kartonæsker EU/1/10/642/002 84 filmovertrukne tabletter i PVC/Aclar/PVC Aluminiumsblistre i kartonæsker 
EU/1/10/642/001 28 film-coated tablets in PVC/Aclar/PVC - Aluminium blisters in cardboard boxes EU/1/10/642/002 84 film-coated tablets in PVC/Aclar/PVC - Aluminium blisters in cardboard boxes
Øsofagitis inklusive øsofageale ulcerationer eller strikturer og dysfagi, opkastning, flatulens 
Oesophagitis including oesophageal ulcerations or strictures and dysphagia, Vomiting, Flatulence
På grund af begrænset klinisk erfaring kan Ibandronsyre Teva ikke anbefales til patienter med kreatinin-clearance lavere end 30 ml/min (se pkt. 
Due to limited clinical experience, Ibandronic Acid Teva is not recommended for patients with a creatinine clearance below 30 ml/min (see section 5.2).
Hvis det er muligt, bør det overvejes at seponere behandlingen med Ibandronsyre Teva midlertidigt, indtil tilstanden forbedres og risikofaktorerne for knoglenekrose i kæben er reduceret. 
Temporary interruption of Ibandronic Acid Teva treatment should be considered until the condition resolves and contributing risk factors are mitigated where possible.
For disse patienter var der ingen forskel i incidensen af øvre gastrointestinale bivirkninger, uanset om de fik 150 mg én gang om måneden eller 2,5 mg daglig. 
For these patients, there was no difference in the incidence of upper gastrointestinal adverse events with the 150 mg once monthly regimen compared to the 2.5 mg daily regimen.
Knoglemineraltæthed (BMD) 
Bone mineral density (BMD)
De mest alvorlige indberettede bivirkninger er anafylaktisk reaktion/shock, atypiske femurfrakturer, knoglenekrose i kæben, gastrointestinal irritation, inflammation i øjet, (se afsnittet ”Beskrivelse af udvalgte bivirkninger ” og pkt. 
The most serious reported adverse reactions are anaphylactic reaction/shock, atypical fractures of the femur, osteonecrosis of the jaw, gastrointestinal irritation, ocular inflammation, (see paragraph “Description of selected adverse reactions” and section 4.4).
Der er ingen relevant nedsættelse af biotilgængeligheden, når ibandronsyre indtages 60 minutter før dagens første måltid. 
There is no meaningful reduction in bioavailability provided ibandronic acid is taken 60 minutes before the first food of the day.